

Tatsuro Yamaguchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1655074/publications.pdf>

Version: 2024-02-01

47
papers

737
citations

471509

17
h-index

610901

24
g-index

49
all docs

49
docs citations

49
times ranked

1110
citing authors

#	ARTICLE	IF	CITATIONS
1	Upper gastrointestinal tumors are unrelated to the <i>APC</i> genotype in <i>APC</i>-associated polyposis. Japanese Journal of Clinical Oncology, 2022, , .	1.3	0
2	Risk of first onset of colorectal cancer associated with alcohol consumption in Lynch syndrome: a multicenter cohort study. International Journal of Clinical Oncology, 2022, 27, 1051-1059.	2.2	4
3	Current clinical practice for familial adenomatous polyposis in Japan: A nationwide multicenter study. Annals of Gastroenterological Surgery, 2022, 6, 778-787.	2.4	4
4	A nationwide, multi-institutional collaborative retrospective study of colorectal neuroendocrine tumors in Japan. Annals of Gastroenterological Surgery, 2021, 5, 215-220.	2.4	11
5	Prevalence and molecular characteristics of DNA mismatch repair deficient endometrial cancer in a Japanese hospital-based population. Japanese Journal of Clinical Oncology, 2021, 51, 60-69.	1.3	11
6	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer. Cancer Science, 2021, 112, 1567-1578.	3.9	5
7	Clinicopathological Characteristics of Low-Grade Appendiceal Mucinous Neoplasm. Digestive Surgery, 2021, 38, 222-229.	1.2	8
8	Comprehensive analysis of DNA mismatch repair-deficient gastric cancer in a Japanese hospital-based population. Japanese Journal of Clinical Oncology, 2021, 51, 886-894.	1.3	2
9	Germline deletion of chromosome 2p16-21 associated with Lynch syndrome. Human Genome Variation, 2021, 8, 19.	0.7	1
10	APC germline variant analysis in the adenomatous polyposis phenotype in Japanese patients. International Journal of Clinical Oncology, 2021, 26, 1661-1670.	2.2	7
11	Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study. International Journal of Clinical Oncology, 2021, 26, 1881-1889.	2.2	8
12	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer. International Journal of Clinical Oncology, 2021, 26, 1353-1419.	2.2	67
13	Identification of Lynch syndrome-associated DNA mismatch repair-deficient bladder cancer in a Japanese hospital-based population. International Journal of Clinical Oncology, 2021, 26, 1524-1532.	2.2	2
14	A multicentre confirmatory single-arm trial of the safety and efficacy of a transanal drain for prevention of anastomotic leakage after surgery for rectal cancer. Colorectal Disease, 2021, , .	1.4	7
15	Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. European Journal of Cancer, 2021, 154, 296-306.	2.8	5
16	Prevalence and clinicopathological/molecular characteristics of mismatch repair protein-deficient tumours among surgically treated patients with prostate cancer in a Japanese hospital-based population. Japanese Journal of Clinical Oncology, 2021, 51, 639-645.	1.3	4
17	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2021, , .	1.3	6
18	Stereotactic body radiotherapy for bone metastases in patients with colorectal cancer. Japanese Journal of Clinical Oncology, 2020, 50, 1442-1446.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Long-term outcome of liver resection for colorectal metastases in the presence of extrahepatic disease: A multi-institutional Japanese study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 810-818.	2.6	13
20	Microsatellite instability is inversely associated with type 2 diabetes mellitus in colorectal cancer. <i>PLoS ONE</i> , 2019, 14, e0215513.	2.5	8
21	The single-base-pair deletion, MSH2 c.2635-3delC affecting intron 15 splicing can be a cause of Lynch syndrome. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 477-480.	1.3	7
22	A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 147-155.	2.3	35
23	Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 504-513.	2.2	11
24	Characteristics of MUTYH variants in Japanese colorectal polyposis patients. <i>International Journal of Clinical Oncology</i> , 2018, 23, 497-503.	2.2	10
25	Tumor development in Japanese patients with Lynch syndrome. <i>PLoS ONE</i> , 2018, 13, e0195572.	2.5	25
26	Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 609-618.	1.3	40
27	Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e741-e749.	2.3	20
28	Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version). <i>Journal of the Anus, Rectum and Colon</i> , 2018, 2, S1-S51.	1.1	32
29	Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age. <i>Cancer Medicine</i> , 2017, 6, 1255-1263.	2.8	27
30	Prognostic impact of hospital volume on familial adenomatous polyposis: a nationwide multicenter study. <i>International Journal of Colorectal Disease</i> , 2017, 32, 1489-1498.	2.2	5
31	A case report of ascending colon adenosquamous carcinoma with BRAF V600E mutation. <i>International Cancer Conference Journal</i> , 2017, 6, 93-97.	0.5	4
32	Current status of prophylactic surgical treatment for familial adenomatous polyposis in Japan. <i>Surgery Today</i> , 2017, 47, 690-696.	1.5	13
33	Postoperative complications after stapled and hand-sewn ileal pouch-anal anastomosis for familial adenomatous polyposis: A multicenter study. <i>Annals of Gastroenterological Surgery</i> , 2017, 1, 143-149.	2.4	14
34	Risk Factors for the Development of Desmoid Tumor After Colectomy in Patients with Familial Adenomatous Polyposis: Multicenter Retrospective Cohort Study in Japan. <i>Annals of Surgical Oncology</i> , 2016, 23, 559-565.	1.5	33
35	Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis. <i>Oncology</i> , 2016, 91, 162-170.	1.9	7
36	Upper gastrointestinal tumours in Japanese familial adenomatous polyposis patients. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 310-315.	1.3	37

#	ARTICLE	IF	CITATIONS
37	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 626.	2.6	13
38	Idiopathic myointimal hyperplasia of mesenteric veins: Rare case of ischemic colitis mimicking inflammatory bowel disease. <i>Digestive Endoscopy</i> , 2015, 27, 768-771.	2.3	21
39	Comparison of clinical features between suspected familial colorectal cancer type X and Lynch syndrome in Japanese patients with colorectal cancer: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 153-159.	1.3	28
40	Validation and Modification of the Japanese Classification System for Liver Metastases from Colorectal Cancer: A Multi-institutional Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 3888-3895.	1.5	5
41	Underexpression of miR-126 and miR-20b in Hereditary and Nonhereditary Colorectal Tumors. <i>Oncology</i> , 2014, 87, 58-66.	1.9	30
42	Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2012, 30, 1690-1696.	2.6	22
43	Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 629-635.	2.3	6
44	Difference in characteristics of <i>APC</i> mutations between colonic and extracolonic tumors of FAP patients: Variations with phenotype. <i>International Journal of Cancer</i> , 2008, 122, 2491-2497.	5.1	31
45	A new classification system for liver metastases from colorectal cancer in Japanese multicenter analysis. <i>Hepato-Gastroenterology</i> , 2008, 55, 173-8.	0.5	25
46	Accumulation Profile of Frameshift Mutations During Development and Progression of Colorectal Cancer From Patients With Hereditary Nonpolyposis Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 399-406.	1.3	28
47	Both BRAF and KRAS mutations are rare in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer. <i>Cancer Letters</i> , 2004, 211, 105-109.	7.2	24